The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Blockade of inhibitory immune signaling between PD-1 and its ligands PD-L1 and PD-L2 is a potential mechanism to promote immune eradication of tumor cells and early phase clinical trials of anti-PD-1 and anti-PD-L1 monoclonal antibodies have demonstrated clinical activity in melanoma, renal cell carcinoma as well as a…”
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 5,997
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 5×
“PD-L1 (also known as B7-H1 or CD274) and PD-L2 are the two known ligands for PD-1 with PD-L1 being the main mediator of immunosuppressive effects(6).”
InfluentialFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 3×
“Programmed death (PD)-1 (also known as CD279), a member of the immunoglobulin superfamily, is a receptor expressed on the surface of activated T-cells, regulatory T cells, B-cells, NK cells, activated monocytes and dendritic cells, that negatively regulates their proliferation and activation(5,6).”
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Cited by
Webb, J. R., Milne, K., Kroeger, D. R., & Nelson, B. H. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.03.008 · Cited by 335
Brody, R., Zhang, Y., Ballas, M., Siddiqui, M. K., Gupta, P., Barker, C., Midha, A., & Walker, J. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.005 · Cited by 317
Heeren, A. M., Punt, S., Bleeker, M. C., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.64 · Cited by 310
Pawelczyk, K., Piotrowska, A., Ciesielska, U., Jablonska, K., Glatzel-Plucinska, N., Grzegrzolka, J., Podhorska-Okolow, M., Dziegiel, P., & Nowinska, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040824 · Cited by 192
“[20] conducted a study on a group of 678 patients.”
BackgroundResultInfluentialPD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
Scheel, A. H., Ansén, S., Schultheis, A. M., Scheffler, M., Fischer, R. N., Michels, S., Hellmich, M., George, J., Zander, T., Brockmann, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1131379 · Cited by 111
Metadata
- Authors
- Cooper, W. A., Tran, T., Vilain, R. E., Madore, J., Selinger, C. I., Kohonen-Corish, M., Yip, P., Yu, B., O’Toole, S. A., McCaughan, B. C., Yearley, J. H., Horvath, L. G., Kao, S., Boyer, M., & Scolyer, R. A.
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 89
- Issue
- 2
- Pages
- 181-188
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W1586178471
- Cited by
- 294
- References
- 46
- FWCI
- 16.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.